Morgan Stanley Adamis Pharmaceuticals Corp Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.1 - $0.3 $1,170 - $3,510	11,700 Added 11.41%	114,218 $13,000
Q4 2022 Feb 14, 2023	BUY	$0.14 - $0.22 $20 - $32	149 Added 0.15%	102,518 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $0.54 $888 - $1,999	-3,702 Reduced 3.49%	102,369 $20,000
Q2 2022 Oct 27, 2022	SELL	$0.34 - $0.57 $1,413 - $2,369	-4,157 Reduced 3.77%	106,071 $53,000
Q2 2022 Aug 15, 2022	SELL	$0.34 - $0.57 $1,413 - $2,369	-4,157 Reduced 3.77%	106,071 $53,000
Q1 2022 Oct 27, 2022	BUY	$0.55 - $0.73 $2,286 - $3,034	4,157 Added 3.92%	110,228 $63,000
Q1 2022 May 13, 2022	SELL	$0.55 - $0.73 $14,814 - $19,662	-26,935 Reduced 19.64%	110,228 $63,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.23 $18,361 - $39,621	32,213 Added 30.69%	137,163 $83,000
Q3 2021 Nov 15, 2021	BUY	$0.92 - $1.18 $96,554 - $123,841	104,950 New	104,950 $102,000

Ticker ADMP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 149,983,008
Market Cap $73.5M
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emerg...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.